Results 171 to 180 of about 118,013 (268)
Impact of an Additional Therapy Guideline-Directed Medical Therapy on 30-Day Readmissions for Heart Failure with Reduced Ejection Fraction. [PDF]
Peterson A +5 more
europepmc +1 more source
ABSTRACT Background In the EASY‐PREDICT Study, patients were randomized to angiography‐guidance or post‐percutaneous coronary intervention (PCI) physiology‐guidance. Discordance between resting and hyperemic physiology post‐PCI might have a different relationship with clinical outcomes.
Paola Ulacia Flores +13 more
wiley +1 more source
Identification, characterisation and outcomes of pre-atrial fibrillation in heart failure with reduced ejection fraction. [PDF]
Helbitz A +15 more
europepmc +1 more source
ABSTRACT Transcatheter aortic valve implantation (TAVI) has become an established treatment for severe aortic stenosis. However, the need for unplanned conversion to cardiac surgery (CS) during TAVI remains an infrequent but critical event. It is unclear whether this risk is higher in patients undergoing urgent procedures.
Nikolaos Ktenopoulos +12 more
wiley +1 more source
Oral nitrate-reducing capacity and aerobic fitness are impaired in older individuals with heart failure with reduced ejection fraction. [PDF]
Stahl ME +7 more
europepmc +1 more source
ABSTRACT Alcohol septal ablation is a well‐established treatment method for patients with hypertrophic cardiomyopathy. We present a case report of a patient with transposition of the great arteries (TGA) after a Mustard procedure, who developed significant right ventricular outflow tract obstruction (RVOTO), functionally resembling subaortic stenosis ...
Vera Osberghaus +6 more
wiley +1 more source
Effectiveness and safety of vericiguat in patients with heart failure and reduced ejection fraction: a narrative review of real-world evidence studies. [PDF]
Escobar C +8 more
europepmc +1 more source
ABSTRACT Background Optical coherence tomography (OCT)‐guided percutaneous coronary intervention (PCI) enhances treatment of complex coronary artery lesions, including left main (LM) disease, by enabling lesion morphology assessment and stent optimization, thereby reducing major adverse cardiac events (MACE).
Prathap Kumar +4 more
wiley +1 more source

